Johnson & Johnson (JNJ) stock is trading lower even after the company raised its 2026 sales forecast.
Defiance ETFs chief investment officer Sylvia Jablonski and Yahoo Finance's Julie Hyman discuss the importance of AI for Johnson & Johnson, pharmaceuticals, and biotech.
source & further reading
ca.finance.yahoo.com — original article
Can AI withstand possible rate hikes from the Fed?
Morgan Stanley had a blowout quarter. But is all this AI-driven revenue sustainable?
Why ASML's sales forecast lift is a 'real vote of confidence' for the AI trade